Formula 3® Antifungal produced by Tetra Cooperation
The active ingredient in Formula 3® is Tolnaftate and is FDA approved for use in the treatment for toenail fungus.
Tolnaftate is an antifungal agent used to treat fungal infections on the skin and foot such athlete's foot. Tolnaftate was synthesized in the early 1950's and was approved as an over-the-counter drug by the U.S. Food and Drug Administration in 1965. Until Formula 3® was developed, Tolnaftate was insoluble in oil or water and was emulsified in all medications and could not penetrate the toenail. Tetra cooperation developed a method to allow Tolnaftate to become soluble in oil thus allowing it to penetrate into the toenail.
Formula 3® is the only oil-based treatment available. It requires no drying time, is odorless, does not stain or leave any residue.
Tolnaftate is compounded with Jojoba oil and when applied to the affected toenail it is absorbed into the toenail. Jojoba oil is an all natural oil. It is virtually identical to the oil produced by our sebaceous glands. It is very similar to the oil your skin produces naturally.
Formula 3® is absorbed in seconds. In addition, it is odorless, does not stain, and leaves no residue.
The oils in Formula 3® actually condition the skin. It is extremely rare to have a hypersensitivity to Tolnaftate, which may result in a minor skin irritation. Simply stop treatment and the skin will clear. See your doctor if the condition persists.
It is recommended to apply Formula 3® to the affected areas twice each day, morning and night. One bottle of Formula 3® will last between 3 - 6 months depending on the total number of toenails infected.
Formula 3® is backed by an unconditional, patient-direct, money-back guarantee. Simply call the 800 number on the bottle, box or instruction sheet for a full refund if you are not completely satisfied.
Find Formula 3@ Here
The articles and content contained in this website are the exclusive property of PodiatryNetwork.com and PhysicianWebPages.com. Any reproduction or transfer to other websites or print publications without prior written consent is strictly prohibited.